1. DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener 14:32. https://doi.org/10.1186/s13024-019-0333-5
2. Henriques AG, Müller T, Oliveira JM, Cova M, da Cruz e Silva CB, da Cruz e Silva OAB (2016) Altered protein phosphorylation as a resource for potential AD biomarkers. Sci Rep 2016;6:30319. https://doi.org/10.1038/srep30319
3. Henriques AG, Vieira SI, da Cruz E Silva EF, da Cruz e Silva OAB (2010) Aβ promotes Alzheimer’s disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. J Neurochem 113:761–71. https://doi.org/10.1111/j.1471-4159.2010.06643.x
4. Domingues C, da Cruz e Silva OAB, Henriques AG (2017) Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks. Curr Alzheimer Res 14:870–82. https://doi.org/10.2174/1567205014666170317113606
5. Blennow K, Zetterberg H (2009) Cerebrospinal fluid biomarkers for Alzheimer’s disease. J Alzheimers Dis 18:413–7. https://doi.org/10.3233/JAD-2009-1177
6. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki H-W, et al (2009) Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 116:203–12. https://doi.org/10.1007/s00702-008-0177-6
7. Hampel H, O’Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, et al (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 14:639–52. https://doi.org/10.1038/s41582-018-0079-7
8. Kowal J, Tkach M, Théry C (2014) Biogenesis and secretion of exosomes. Curr Opin Cell Biol 29:116–25. https://doi.org/10.1016/j.ceb.2014.05.004
9. Armstrong D, Wildman DE (2018) Extracellular Vesicles and the Promise of Continuous Liquid Biopsies. J Pathol Transl Med 52:1–8. https://doi.org/10.4132/jptm.2017.05.21
10. Kanninen KM, Bister N, Koistinaho J, Malm T (2016) Exosomes as new diagnostic tools in CNS diseases. Biochim Biophys Acta 1862:403–10. https://doi.org/10.1016/j.bbadis.2015.09.020
11. Soares Martins T, Trindade D, Vaz M, Campelo I, Almeida M, Trigo G, et al (2020) Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease. J Neurochem 156:162–81. https://doi.org/10.1111/jnc.15112
12. Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al (2015) Identification of preclinical Alzheimer’s disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement 11:600-7.e1. https://doi.org/10.1016/j.jalz.2014.06.008
13. Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach I V., Goetzl L, et al (2016) Cargo proteins of plasma astrocyte‐derived exosomes in Alzheimer’s disease. FASEB J 30:3853–9. https://doi.org/10.1096/fj.201600756R
14. Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, et al (2019) Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 76:1340–51. https://doi.org/10.1001/jamaneurol.2019.2462
15. Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach I V, Goetzl L, Abner EL, et al (2016) Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J 30:4141–8. https://doi.org/10.1096/fj.201600816R
16. Goetzl EJ, Schwartz JB, Abner EL, Jicha GA, Kapogiannis D (2018) High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol 83:544–52. https://doi.org/10.1002/ana.25172
17. Winston CN, Goetzl EJ, Schwartz JB, Elahi FM, Rissman RA (2019) Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer’s disease dementia. Alzheimers Dement (Amst) 11:61–6. https://doi.org/10.1016/j.dadm.2018.11.002
18. Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst) 2016;3:63–72.
19. Cheng L, Doecke JD, Sharples RA, Villemagne VL, Fowler CJ, Rembach A, et al (2015) Prognostic serum miRNA biomarkers associated with Alzheimer’s disease shows concordance with neuropsychological and neuroimaging assessment. Mol Psychiatry 20:1188–96. https://doi.org/10.1038/mp.2014.127
20. Lugli G, Cohen AM, Bennett DA, Shah RC, Fields CJ, Hernandez AG, et al (2015) Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One 10:e0139233. https://doi.org/10.1371/journal.pone.0139233
21. Soares Martins T, Magalhães S, Rosa IM, Vogelgsang J, Wiltfang J, Delgadillo I, et al (2020) Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer’s Disease Discrimination: A Pilot Study. J Alzheimer’s Dis 74:391–405. https://doi.org/10.3233/JAD-191034
22. Su H, Rustam YH, Masters CL, Makalic E, McLean CA, Hill AF, et al (2021) Characterization of brain‐derived extracellular vesicle lipids in Alzheimer’s disease. J Extracell Vesicles 10:e12089. https://doi.org/10.1002/jev2.12089
23. Oeckl P, Otto M (2019) A Review on MS-Based Blood Biomarkers for Alzheimer’s Disease. Neurol Ther 8:113–27. https://doi.org/10.1007/s40120-019-00165-4
24. Rosa IM, Henriques AG, Carvalho L, Oliveira J, da Cruz e Silva OAB (2017) Screening Younger Individuals in a Primary Care Setting Flags Putative Dementia Cases and Correlates Gastrointestinal Diseases with Poor Cognitive Performance. Dement Geriatr Cogn Disord 43:15–28. https://doi.org/10.1159/000452485
25. Rosa IM, Henriques AG, Wiltfang J, da Cruz E Silva OAB (2018) Putative Dementia Cases Fluctuate as a Function of Mini-Mental State Examination Cut-Off Points. J Alzheimers Dis 61:157–67. https://doi.org/10.3233/JAD-170501
26. Shahpasand-Kroner H, Klafki H-W, Bauer C, Schuchhardt J, Hüttenrauch M, Stazi M, et al (2018) A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease. Alzheimers Res Ther 10:121. https://doi.org/10.1186/s13195-018-0448-x
27. Vogelgsang J, Shahpasand-Kroner H, Vogelgsang R, Streit F, Vukovich R, Wiltfang J (2018) Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer’s disease and dementia not due to Alzheimer’s disease. Exp Brain Res 236:1241–50. https://doi.org/10.1007/s00221-018-5210-x
28. Soares Martins T, Catita J, Martins Rosa I, A. B. da Cruz e Silva O, Henriques AG, da Cruz e Silva OAB, et al (2018) Exosome isolation from distinct biofluids using precipitation and column-based approaches. PLoS One 13:e0198820. https://doi.org/10.1371/journal.pone.0198820
29. Soares Martins T, Marçalo R, Ferreira M, Vaz M, Silva RM, Rosa IM, et al (2021) Exosomal Aβ-binding proteins identified by “in silico” analysis represent putative blood-derived biomarker candidates for alzheimer´s disease. Int J Mol Sci 22:3933. https://doi.org/10.3390/ijms22083933
30. Shevchenko A, Tomas H, Havli\[sbreve] J, Olsen J V, Mann M (2007) In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 1:2856–60. https://doi.org/10.1038/nprot.2006.468
31. Chong J, Wishart DS, Xia J (2019) Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr Protoc Bioinforma 68:e86. https://doi.org/10.1002/cpbi.86
32. Vanni S, Moda F, Zattoni M, Bistaffa E, De Cecco E, Rossi M, et al (2017) Differential overexpression of SERPINA3 in human prion diseases. Sci Rep 7:15637. https://doi.org/10.1038/s41598-017-15778-8
33. Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell 52:487–501. https://doi.org/10.1016/0092-8674(88)90462-X
34. Licastro F, Mallory M, Hansen LA, Masliah E (1998) Increased levels of α-1-antichymotrypsin in brains of patients with Alzheimer’s disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol 88:105–10. https://doi.org/10.1016/S0165-5728(98)00096-4
35. Padmanabhan J, Levy M, Dickson DW, Potter H (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer’s disease brain, induces tau phosphorylation in neurons. Brain 129:3020–34. https://doi.org/10.1093/brain/awl255
36. Licastro F, Parnetti L, Morini M, Davis L, Cucinotta D, Gaiti A, et al (1995) Acute Phase Reactant Alpha 1-antichymotrypsin Is Increased in Cerebrospinal Fluid and Serum of Patients With Probable Alzheimer Disease. Alzheimer Dis Assoc Disord 9:112–8. https://doi.org/10.1097/00002093-199509020-00009
37. Matsubara E, Hirai S, Amari M, Shoji M, Yamaguchi H, Okamoto K, et al (1990) α1‐Antichymotrypsin as a possible biochemical marker for Alzheimer‐type dementia. Ann Neurol 28:561–7. https://doi.org/10.1002/ana.410280414
38. Delamarche C, Berger F, Gallard L, Pouplard-Barthelaix A (1991) Aging and Alzheimer’s disease: Protease inhibitors in cerebrospinal fluid. Neurobiol Aging 12:71–4. https://doi.org/10.1016/0197-4580(91)90042-i
39. Furby A, Leys D, Delacourte A, Buee L, Soetaert G, Petit H (1991) Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer’s disease? J Neurol Neurosurg Psychiatry 54:469. https://doi.org/10.1136/jnnp.54.5.469
40. Pirttila T, Mehta PD, Frey H, Wisniewski HM (1994) α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer’s disease. Neurobiol Aging 15:313–7. https://doi.org/10.1016/0197-4580(94)90026-4
41. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12:215–27. https://doi.org/10.1097/00002093-199809000-00016
42. Lawlor BA, Swanwick GRJ, Feighery C, Walsh JB, Coakley D (1996) Acute phase reactants in Alzheimer’s disease. Biol Psychiatry 39:1051–2. https://doi.org/10.1016/0006-3223(95)00426-2
43. Matsubara E, Amari M, Shoji M, Harigaya Y, Yamaguchi H, Okamoto K, et al (1989) Serum concentration of alpha 1-antichymotrypsin is elevated in patients with senile dementia of the Alzheimer type. Prog Clin Biol Res 317:707–14.
44. Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T (1992) Serological α1‐Antichymotrypsin in Down’s syndrome and Alzheimer’s disease. Ann Neurol 32:193–7. https://doi.org/10.1002/ana.410320211
45. Altstiel LD, Lawlor B, Mohs R, Schmeidler J, Dalton A, Mehta P, et al (1995) Elevated alpha1-antichymotrypsin serum levels in a subset of nondemented first-degree relatives of Alzheimer’s disease patients. Dement Geriatr Cogn Disord 6:17–20. https://doi.org/10.1159/000106917
46. Lieberman J, Schleissner L, Tachiki KH, Kling AS (1995) Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol Aging 16:747–53. https://doi.org/10.1016/0197-4580(95)00056-k
47. DeKosky ST, Ikonomovic MD, Wang X, Farlow M, Wisniewski S, Lopez OL, et al (2003) Plasma and cerebrospinal fluid α1-antichymotrypsin levels in Alzheimer’s disease: Correlation with cognitive impairment. Ann Neurol 53:81–90. https://doi.org/10.1002/ana.10414
48. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, et al (2007) Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69:1569–79. https://doi.org/10.1212/01.wnl.0000271077.82508.a0
49. Porcellini E, Davis E, Chiappelli M, Ianni E, Di Stefano G, Forti P, et al (2008) Elevated Plasma Levels of alpha-1-Anti-Chymotrypsin in Age-Related Cognitive Decline and Alzheimers Disease: A Potential Therapeutic Target. Curr Pharm Des 14:2659–64. https://doi.org/10.2174/138161208786264151
50. Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, et al (2000) Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer’s disease: Peripheral inflammation or signals from the brain? J Neuroimmunol 103:97–102. https://doi.org/10.1016/S0165-5728(99)00226-X
51. Nilsson LNGG, Bales KR, DiCarlo G, Gordon MN, Morgan D, Paul SM, et al (2001) α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer’s Disease. J Neurosci 21:1444–51. https://doi.org/10.1523/JNEUROSCI.21-05-01444.2001
52. Tyagi E, Fiorelli T, Norden M, Padmanabhan J (2013) Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer’s Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation. Int J Alzheimers Dis 2013:606083. https://doi.org/10.1155/2013/606083
53. Shih Y-HH, Tsai K-JJ, Lee C-WW, Shiesh S-CC, Chen W-TT, Pai M-CC, et al (2014) Apolipoprotein C-III is an Amyloid-β-Binding Protein and an Early Marker for Alzheimer’s Disease. J Alzheimers Dis 41:855–65. https://doi.org/10.3233/JAD-140111
54. Öhrfelt A, Andreasson U, Simon A, Zetterberg H, Edman Å, Potter W, et al (2011) Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra 1:31–42. https://doi.org/10.1159/000323417
55. Fei S, Anne P, John C, Nicole A K, Wei W, Barbara C, et al (2012) Plasma Apolipoprotein Levels Are Associated With Cognitive Status and Decline in a Community Cohort of Older Individuals. PLoS One 7:e34078. https://doi.org/10.1371/journal.pone.0034078
56. Trouw LA, Nielsen HM, Minthon L, Londos E, Landberg G, Veerhuis R, et al (2008) C4b-binding protein in Alzheimer’s disease: binding to Abeta1-42 and to dead cells. Mol Immunol 45:3649–60. https://doi.org/10.1016/j.molimm.2008.04.025
57. Song F, Poljak A, Kochan NA, Raftery M, Brodaty H, Smythe GA, et al (2014) Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics. Proteome Sci 12:5. https://doi.org/10.1186/1477-5956-12-5
58. Castora FJ, Conyers BL, Gershon BS, Kerns KA, Campbell, R, Simsek-Duran F (2019) The T9861C Mutation in the mtDNA-Encoded Cytochrome C Oxidase Subunit III Gene Occurs in High Frequency but with Unequal Distribution in the Alzheimer’s Disease Brain. J Alzheimers Dis 72:257–69. https://doi.org/10.3233/JAD-190176
59. Loeffler DA, Camp DM, Bennett DA (2008) Plaque complement activation and cognitive loss in Alzheimer’s disease. J Neuroinflammation 5:9. https://doi.org/10.1186/1742-2094-5-9
60. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol 154:927–36. https://doi.org/10.1016/S0002-9440(10)65340-0
61. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA (1993) Alpha 1‐Antichymotrypsin Binding to Alzheimer Aβ Peptides Is Sequence Specific and Induces Fibril Disaggregation In Vitro. J Neurochem 61:298–305. https://doi.org/10.1111/j.1471-4159.1993.tb03568.x
62. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G (1992) α1-Antitrypsin and α1-antichymotrypsin are in the lesions of Alzheimer’s disease. Neuroreport 3:201–3. https://doi.org/10.1097/00001756-199202000-00020
63. Sun YX, Wright HT, Janciauskiene S (2002) α1-antichymotrypsin/Alzheimer’s peptide Aβ1-42 complex perturbs lipid metabolism and activates transcription factors PPARγ and NFκB in human neuroblastoma (Kelly) cells. J Neurosci Res 67:511–22. https://doi.org/10.1002/jnr.10144
64. Oliveira J, Costa M, de Almeida MSC, da Cruz E Silva OAB, Henriques AG (2017) Protein Phosphorylation is a Key Mechanism in Alzheimer’s Disease. J Alzheimers Dis 58:953–78. https://doi.org/10.3233/JAD-170176
65. Oliveira JM, da Cruz E Silva CB, Müller T, Martins TS, Cova M, da Cruz E Silva OAB, et al (2017) Toward Neuroproteomics in Biological Psychiatry: A Systems Approach Unravels Okadaic Acid-Induced Alterations in the Neuronal Phosphoproteome. OMICS 21:550–63. https://doi.org/10.1089/omi.2017.0108